Filling A Prescription? You Might Be Better Off Paying Cash
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
The independent source for health policy research, polling, and news.
661 - 680 of 697 Results
Amid growing concern about rising drug costs, the practices of prescription benefit management firms are drawing a new level of attention.
Staff researchers at California’s largest public buyer of health benefits say the goal of reducing drug costs for the state is appealing but might not work in the real world.
The Medicare Payment Advisory Commission outlined a package of changes to Medicare’s drug program that could save billions of dollars.
The Food and Drug Administration has introduced a simplified form that doctors will use to seek FDA approval to treat seriously ill patients with experimental drugs after other options run out.
Thousands of Floridians patronize storefront businesses that help them buy cheaper drugs online from Canada and other countries, but the Food and Drug Administration calls the practice illegal and risky.
A refrigerator-sized machine could someday make lifesaving drugs on site when outbreaks occur or where medicine is in short supply, like on the battlefield.
The FDA could soon approve an implantable form of a drug used to treat opioid addiction. While the approach helped patients avoid relapse in tests, its price may be prohibitive for some, doctors say.
A proposal to change the way Medicare pays for some drugs has set off intense reaction and lobbying — all tied to a common theme: How far should the government go in setting prices for prescription drugs?
UnitedHealth’s OptumRx is the lowest bidder and wins a key endorsement ahead of final vote by California’s public retirement system.
The U.S. faces a variety of serious concerns beyond just the future of the federal health law.
In June, California will become the fifth state to allow terminally ill patients to end their lives with prescriptions from their doctors, but getting those prescriptions will require serious effort.
The analysis by Avalere examines changes in how silver plans on the insurance marketplaces handle coverage for high-cost specialty drugs.
How high-cost drugs are impacting California.
A study published in Health Affairs examines how physician-patient interactions often present missed opportunities to control patients’ health care spending.
An MIT economist and Harvard oncologist propose offering loans to patients to cover the cost of expensive, curative drugs, financed by private sector investment in loan securities.
Valeant Pharmaceuticals, the company that makes Seconal, the drug most commonly used in prescribed for terminally ill patients who want to end their lives, physician-assisted suicide, has doubled the price to more than $3,000.
More Medicare Part D drug plans are requiring coinsurance rather than copayments for more types of medications, making beneficiaries’ costs less predictable.
The proposal that Medicare made this month to better control prescription drug costs involves testing strategies used with some success in the private sector.
New Hampshire is expanding its website that lists the cost of specific medical procedures to include dental treatments and 65 prescription drugs. California is expanding its report cards on large medical groups to include cost of medical services by an average patient.
Regulators unveiled a two-part plan that will change payments and test ways in which the Medicare Part B program can change the incentives that some policy experts say encourage doctors to choose higher-cost medications.
© 2026 KFF